Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Cetuximab vs Cetuximab in CDKN2A-altered, HPV-unrelated HNSCC
NCT04966481Phase 3Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2022
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palbociclib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Overall survival at 15 months. Started Apr 2022; status: recruiting.
02
Drugs
palbociclib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04966481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966481.